Novo Nordisk's Buyback and CagriSema Data Address Different Questions Than Its US Problem
Published on 10/22/2026 at 11:31 | Editorial boerse-global.de
Novo Nordisk is returning capital to shareholders at a steady clip while its most closely watched pipeline asset posts encouraging numbers in a subgroup of patients. Neither development, on its own, answers the question hanging over the stock: how much pressure is building in the US business before new medicines can shift the narrative?
The Danish drugmaker said Monday it had repurchased more shares under its existing buyback, a twelve-month programme launched on 4 February with a ceiling of up to DKK 15 billion. The latest disclosure documents continued execution — it announces neither a fresh programme nor an increase to the existing envelope.
Capital returns are not revenue growth
That distinction matters for anyone trying to read the shares. Buybacks speak to how Novo Nordisk deploys capital; they say nothing about the trajectory of its medicine sales. Investors therefore have to keep capital measures and operating earnings prospects in separate compartments.
BMO Capital's take sits squarely on the operating side. Analyst Evan Seigerman trimmed his price target to $40 from $47 on 12 October, keeping a "Market Perform" rating. He pointed to a tough year-earlier comparison and eroding US market share, both of which he expects could weigh on Ozempic revenue in the third quarter of 2026. The comparison is explicitly against the third quarter of 2025 — an expectation, not reported figures.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A positive signal with clear limits
Offsetting that concern is the detailed CagriSema readout already made public. According to Novo Nordisk, the post-hoc analysis of the Phase 3 REDEFINE 1 trial covered 2,309 women, whose average weight loss reached 25.0% after 68 weeks on the assumption of treatment adherence. The placebo arm averaged a 3.0% reduction.
The framing deserves care. These are exploratory analyses conducted after the study concluded, and CagriSema is not approved. The full trial had shown 22.7% weight loss, falling short of the company's 25% goal. Reuters characterised the findings as possible support for CagriSema's potential as a Wegovy successor.
Where the sell-side stands
Analyst reactions illustrate why clinical progress and equity valuation are best judged apart. A sharply raised target can coexist with an unchanged, cautious recommendation. Oddo BHF lifted its Novo Nordisk price target to DKK 305 from DKK 221 on Tuesday while leaving its rating at "Neutral" — a higher number without a more constructive call.
The split views are not simply contradictory. CagriSema's data are a clinical finding; the risks BMO cites are commercial ones. One does not follow directly from the other.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The next hard checkpoint
Novo Nordisk plans to publish financial results for the first nine months of 2026 on 4 November 2026. That date offers the next concrete occasion to assess the business alongside the study news.
For investors, the takeaway is a clean separation of issues. The post-hoc CagriSema analyses deliver a positive efficacy finding for the women studied. Whether the economic picture improves at the same time has to be judged from the numbers — a loftier price target answers that no better than a single trial result.
Ad
Novo Nordisk Stock: New Analysis - 22 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
